Literature DB >> 21559909

Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

Mitsuhiro Imasawa1, Yoichi Sakurada2, Hiroyuki Iijima2.   

Abstract

PURPOSE: To investigate the characteristics of eyes with polypoidal choroidal vasculopathy (PCV) which develop secondary classic choroidal neovascularization (CNV) after photodynamic therapy (PDT).
METHODS: We retrospectively reviewed the records of 64 eyes of 64 PCV patients (43 men, 21 women; mean age ± standard deviation, 72.7 ± 8.6 years), who were followed-up for at least 1 year after the initial PDT. There was no evidence of classic CNV in any of the subject eyes on fluorescein angiography (FA) at the first PDT. Eyes which developed of secondary classic CNV after PDT were classified as the CNV group and the other eyes as the No-CNV group.
RESULTS: Secondary classic CNV developed after PDT in 10 (15.6%) of the 64 eyes. Six patients developed CNV within 1 year after the first PDT. Multivariate logistic regression analysis for the baseline factors related to CNV development, including age, gender, greatest linear dimension, and the lesion components, revealed that in the CNV group the age was significantly younger (p = 0.037) and the incidence of retinal edema was significantly greater (p = 0.041) than in the No-CNV group.
CONCLUSIONS: Secondary classic CNV tends to develop after PDT in PCV eyes in younger patients with retinal edema.

Entities:  

Mesh:

Year:  2011        PMID: 21559909     DOI: 10.1007/s10384-011-0006-6

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  24 in total

1.  Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  Kenji Yamashiro; Akitaka Tsujikawa; Akihiro Nishida; Michiko Mandai; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

2.  Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Yumiko Kurashige; Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2008-07-09       Impact factor: 5.258

3.  Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Peter Stalmans; Claus Eckardt; Matthias Lüke; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

4.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

5.  Polypoidal choroidal vasculopathy: natural history.

Authors:  Masanobu Uyama; Mitsumasa Wada; Yoshimi Nagai; Takashi Matsubara; Hiroshi Matsunaga; Ichiro Fukushima; Kanji Takahashi; Miyo Matsumura
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

6.  Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.

Authors:  Olcay Tatar; Edwin Kaiserling; Annemarie Adam; Faik Gelisken; Kei Shinoda; Michael Völker; Bart A Lafaut; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Arch Ophthalmol       Date:  2006-06

7.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

8.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

9.  Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroko Aikawa; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2007-04-30       Impact factor: 5.258

10.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

View more
  2 in total

1.  Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis.

Authors:  Kai Tang; Jun-Kang Si; Da-Dong Guo; Yan Cui; Yu-Xiang Du; Xue-Mei Pan; Hong-Sheng Bi
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

2.  Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup.

Authors:  Maribel Fernández; María Gil; Francisco Gomez-Ulla; Pablo Charlón
Journal:  Case Rep Med       Date:  2012-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.